Regenerative Therapy and Immune Modulation Using Umbilical Cord Blood-Derived Cells

被引:35
作者
Damien, Pauline [1 ]
Allan, David S. [1 ,2 ,3 ]
机构
[1] Univ Ottawa, Ctr Transfus Res, Ottawa, ON, Canada
[2] Ottawa Hosp Res Inst, Regenerat Med Program, Ottawa, ON K1H 8L6, Canada
[3] Univ Ottawa, Dept Med Hematol, Ottawa, ON, Canada
关键词
Umbilical cord blood; Regenerative medicine; Mesenchymal stromal cells; Endothelial progenitor cells; Cellular therapy; Immunomodulation; MESENCHYMAL STEM-CELLS; ENDOTHELIAL PROGENITOR CELLS; HUMAN BONE-MARROW; ALDEHYDE DEHYDROGENASE-ACTIVITY; HUMAN PLATELET LYSATE; STROMAL CELLS; IN-VITRO; GENE-THERAPY; ADIPOSE-TISSUE; CEREBRAL-ISCHEMIA;
D O I
10.1016/j.bbmt.2015.05.022
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Since the first cord blood transplantation in 1988, umbilical cord blood has become an important option as a source of cells for hematopoietic transplantation. Beyond its role in regenerating the blood and immune systems to treat blood diseases and inherited metabolic disorders, the role of nonhematopoietic progenitor cells in cord blood has led to new and emerging uses of umbilical cord blood in regenerative therapy and immune modulation. In this review, we provide an update on the clinical and preclinical studies using cord blood derived cells such as mesenchymal stromal cells, endothelial-like progenitor cells, and others. We also provide insight on the use of cord blood cells as vehicles for the delivery of therapeutic agents through gene therapy and microvesicle-associated strategies. Moreover, cord blood can provide essential reagents for regenerative applications. Clinical activity using cord blood cells is increasing rapidly and this review aims to provide an important update on the tremendous potential within this fast-moving field. (C) 2015 American Society for Blood and Marrow Transplantation.
引用
收藏
页码:1545 / 1554
页数:10
相关论文
共 100 条
[21]   Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement [J].
Dominici, M. ;
Le Blanc, K. ;
Mueller, I. ;
Slaper-Cortenbach, I. ;
Marini, F. C. ;
Krause, D. S. ;
Deans, R. J. ;
Keating, A. ;
Prockop, D. J. ;
Horwitz, E. M. .
CYTOTHERAPY, 2006, 8 (04) :315-317
[22]  
Effenberg A., 2014, CELL TRANSPLANT
[23]   Mesenchymal progenitor cells in human umbilical cord blood [J].
Erices, A ;
Conget, P ;
Minguell, JJ .
BRITISH JOURNAL OF HAEMATOLOGY, 2000, 109 (01) :235-242
[24]   UC blood-derived mesenchyrnal stromal cells: an overview [J].
Flynn, A. ;
Barry, F. ;
O'Brien, T. .
CYTOTHERAPY, 2007, 9 (08) :717-726
[25]   Immunological and regenerative properties of cord blood stem cells [J].
Francese, Roberto ;
Fiorina, Paolo .
CLINICAL IMMUNOLOGY, 2010, 136 (03) :309-322
[26]   In vitro mesengenic potential of human umbilical cord blood-derived mesenchymal stem cells [J].
Gang, EJ ;
Hong, SH ;
Jeong, JA ;
Hwang, SH ;
Kim, SW ;
Yang, IH ;
Ahn, CY ;
Han, H ;
Kim, H .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2004, 321 (01) :102-108
[27]   The dynamic in vivo distribution of bone marrow-derived mesenchymal stent cells after infusion [J].
Gao, JZ ;
Dennis, JE ;
Muzic, RF ;
Lundberg, M ;
Caplan, AI .
CELLS TISSUES ORGANS, 2001, 169 (01) :12-20
[28]   Multilineage differentiation activity by cells isolated from umbilical cord blood: Expression of bone, fat, and neural markers [J].
Goodwin, HS ;
Bicknese, AR ;
Chien, SN ;
Bogucki, BD ;
Oliver, DA ;
Quinn, CO ;
Wall, DA .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2001, 7 (11) :581-588
[29]   Serum-free media for the production of human mesenchymal stromal cells: a review [J].
Gottipamula, S. ;
Muttigi, M. S. ;
Kolkundkar, U. ;
Seetharam, R. N. .
CELL PROLIFERATION, 2013, 46 (06) :608-627
[30]   Cationic Liposome-Mediated CXCR4 Gene Delivery into Hematopoietic Stem/Progenitor Cells: Implications for Clinical Transplantation and Gene Therapy [J].
Gul-Uludag, Hilal ;
Xu, Peng ;
Marquez-Curtis, Leah A. ;
Xing, James ;
Janowska-Wieczorek, Anna ;
Chen, Jie .
STEM CELLS AND DEVELOPMENT, 2012, 21 (10) :1587-1596